Full Press Release Details
Medical Announces Receiving a Notification of Granting a Patent Right for its ViRob Technology Platform in China
MA - May 23, 2018 - Microbot Medical Inc. (Nasdaq CM: MBOT), a medical device company specializing in the design and
development of transformational micro-robotic medical technologies, today announced that the State Intellectual Property Office
of China has issued a Notification of Granting a Patent Right for Chinese Patent Application No. 201410432156.7, which covers
the Company's ViRobTM technology platform.
is another significant milestone to protect and differentiate Microbot's unique IP assets, especially as it relates to our
technology platform, such as ViRob , from which we anticipate to deliver multiple novel products, including our SCS,"
commented Harel Gadot, CEO, President and Chairman. "We have worked to expand our patent estate and we anticipate additional
patent allowances in the coming weeks as we seek to protect our ViRob and TipCAT technology platforms. Coupled with
the recent news about the successful conclusion of the pre-clinical study assessing the Company's Self-Cleaning Shunt performed
at Wayne State University by Dr. Carolyn Harris, we are continuing to execute against our goals which allow us to get closer to
delivering our solutions to the market, protecting them and increasing shareholder value."
application covers an autonomous vibration-driven device for motion through a lumen. The device includes a body and an array of
flexible fibers attached thereto, with at least some of the fibers maintaining contact with the inner wall of the lumen and having
anisotropic surface friction therewith, such that mutual vibratory motion between the device and the inner wall of the lumen causes
the device to move along the lumen.
Microbot Medical, Inc.
which was founded in 2010 and commenced operations in 2011, became a NASDAQ listed company on November 28, 2016. The Company specializes
in transformational micro-robotic medical technologies leveraging the natural and artificial lumens within the human body. Microbot's
current platforms, ViRob and TipCAT , are comprised of two highly advanced micro-robotic technologies, from which
the Company is currently developing its first two product candidates: the Self Cleaning Shunt, or SCS , for the treatment
of hydrocephalus and Normal Pressure Hydrocephalus, or NPH; and a self-propelling, semi-disposable endoscope that is being developed
initially for use in colonoscopy procedures. Further information about Microbot Medical is available at http://www.microbotmedical.com.
ViRob technology is a revolutionary autonomous crawling micro-robot which can be controlled remotely or within the body.
Its miniature dimensions allow it to navigate and crawl in different spaces within the human body, including blood vessels, the
digestive tract and the respiratory system. Its unique structure gives it the ability to move in tight spaces and curved passages
as well as the ability to remain within the human body for prolonged time. To learn more about ViRob please visit http://www.microbotmedical.com/technology/virob/.
is a transformational self-propelled, flexible, and semi-disposable endoscope providing see & treat capabilities within tubular
lumens in the human body such as the colon, blood vessels, and the urinary tract. Its locomotion mechanism is perfectly suitable
to navigate and crawl through natural & artificial tubular lumens, applying the minimal necessary pressure to achieve the
adequate friction required for gentle, fast, and safe advancement within the human body. To learn more about TipCAT visit
pertaining to future financial and/or operating results, future growth in research, technology, clinical development, and potential
opportunities for Microbot Medical Inc. and its subsidiaries, along with other statements about the future expectations, beliefs,
goals, plans, or prospects expressed by management constitute forward-looking statements. Any statements that are not historical
fact (including, but not limited to statements that contain words such as "will," "believes," "plans,"
"anticipates," "expects" and "estimates") should also be considered to be forward-looking
statements. Forward-looking statements involve risks and uncertainties, including, without limitation, risks inherent in the development
and/or commercialization of potential products, the outcome of its studies to evaluate the SCS and other existing and future technologies,
uncertainty in the results of clinical trials or regulatory approvals, need and ability to obtain future capital, and maintenance
of intellectual property rights. Actual results may differ materially from the results anticipated in these forward-looking statements
and as such should be evaluated together with the many uncertainties that affect the businesses of Microbot Medical Inc. particularly
those mentioned in the cautionary statements found in Microbot Medical Inc.'s filings with the Securities and Exchange Commission.
Microbot Medical disclaims any intent or obligation to update these forward-looking statements.
and Institutional Investors
Consulting Group llc